Lipoprotein (a) and coronary heart disease among women: Beyond a cholesterol carrier?

European Heart Journal

Volumn 26, Issue 16, 2005, Pages 1633-1639

  Shai, Iris ^a,e   Rimm, Eric B ^a,b   Hankinson, Susan E ^a,b   Cannuscio, Carolyn ^c   Curhan, Gary ^b   Manson, JoAnn E ^a,b   Rifai, Nader ^d   Stampfer, Meir J ^a,b   Ma, Jing ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Apolipoprotein(a); C reactive protein; CHD; Fibrinogen; Lipoprotein(a)

Indexed keywords

ALCOHOL; C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; HORMONE; LIPOPROTEIN A; PLASMINOGEN;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BLOOD; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KRINGLE DOMAIN; MAJOR CLINICAL STUDY; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN INTERACTION;

ADULT; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL; CORONARY DISEASE; EPIDEMIOLOGIC METHODS; FEMALE; FIBRINOGEN; HUMANS; LIPOPROTEIN(A); MIDDLE AGED;

EID: 25844457344     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi222     Document Type: Article

References (34)

1. Milionis HJ, Winder AF, Mikhailidis DP. Lipoprotein (a) and stroke. J Clin Pathol 2000;53:487-496.
2. Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102:1082-1085.
3. Craig WY, Neveux LM, Palomaki GE et al. Lipoprotein (a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998;44:2301-2306.
4. Nguyen TT, Ellefson RD, Hodge DO et al. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 1997;96:1390-1397.
5. Bostom AG, Gagnon DR, Cupples LA et al. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women: the Framingham heart study. Circulation 1994;90:1688-1695.
6. Ridker PM, Hennekens CH, Buring JE et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
7. Craig WY, Ledue TB. Lipoprotein(a) and the acute phase response. Clin Chim Acta 1992;210:231-232.
8. Poon M, Zhang X, Dunsky KG et al. Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation 1997;96:2514-2519.
9. McLean JW, Tomlinson JE, Kuang W et al. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 1987;33:132-137.
10. Angles-Cano E, de la Pena Diaz A, Loyau S. Inhibition of fibrinolysis by lipoprotein(a). Ann N Y Acad Sci 2001;936:261-275.
11. Cantin B, Despres JP, Lamarche B et al. Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study). Am J Cardiol 2002;89:662-666.
12. Scanu AM, Edelstein C. Kringle-dependent structural and functional polymorphism of apolipoprotein(a). Biochim Biophys Acta 1965;1256:1-12.
13. Reblin T, Rader DJ, Beisiegel U et al. Correlation of apolipoprotein(a) isoproteins with Lp(a) density and distribution in fasting plasma. Atherosclerosis 1992;94:223-232.
14. Marcovina SM, Albers JJ, Scanu AM et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 2000;46:1956-1967.
15. Rose G, Blackburn H. Cardiovascular Survey Methods. 2nd ed. Geneva: World Health Organization, 1982.
16. Stampfer MJ, Willett WC, Speizer FE et al. Test of the National Death Index. Am J Epidemiol 1984;119:837-839.
17. Wu K, Helzlsouer KJ, Comstock GW et al. A prospective study on folate, B12, and pyridoxal 5′-phosphate (B6) and breast cancer. Cancer Epidemiol Biomarkers Prev 1999;8:209-217.
18. Glader CA, Birgander LS, Stenlund H et al. Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden. J Intern Med 2002;252:27-35.
19. Stein JH, Rosenson RS. Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med 1997;157:1170-1176.
20. Ridker PM, Rifai N, Rose L et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565.
21. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
22. Boerwinkle E, Leffert CC, Lin J et al. Apolipoprotein (a) gene accounts for greater than 90% of the variation in plasma lipoprotein (a) concentrations. J Clin Invest 1992;90:52-60.
23. Pai JK, Curhan GC, Cannuscio CC et al. Stability of novel plasma markers associated with cardiovascular disease: processing within 36 hours of specimen collection. Clin Chem 2002;48:1781-1784.
24. Kronenberg F, Trenkwalder E, Dieplinger H et al. Lipoprotein(a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail. Arterioscler Thromb Vasc Biol 1996;16:1568-1572.
25. Trenkwalder E, Gruber A, Konig P et al. Increased plasma concentrations of LDL-unbound apo(a) in patients with end-stage renal disease. Kidney Int 1997;52:1685-1692.
26. von Eckardstein A, Schulte H, Cullen P et al. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001;37:434-439.
27. Hopkins PN, Hunt SC, Schreiner PJ et al. Lipoprotein (a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease: results from the NHLBI Family Heart Study. Atherosclerosis 1998;141:333-345.
28. LaRosa JC. Lipids and cardiovascular disease: do the findings and therapy apply equally to men and women? Womens Health Issues 1992;2:102-111.
29. Herrick S, Blanc-Brude O, Gray A et al. Fibrinogen. Int J Biochem Cell Biol 1999;31:741-746.
30. Sangrar W, Bajzar L, Nesheim ME et al. Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation. Biochemistry 1995;34:5151-5157.
31. Palabrica TM, Liu AC, Aronovitz MJ et al. Antifibrinolytic activity of lipoprotein (a) in vivo: human apolipoprotein (a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nature Med 1995;1:256-259.
32. Fey GH, Fuller GM. Regulation of acute phase gene expression by inflammatory mediators. Mol Biol Med 1987;4:323-328.
33. Hunninghake DB, McGovern ME, Koren M et al. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol 2003;26:112-118.
34. Gonbert S, Malinsky S, Sposito AC et al. Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 2002;164:305-311.